ZepZelCaTM ( PHARMAMAR ) Combinado con Keytruda ( INMUNOTERAPIA DE MERCK ) . Dr. Antonio Calles ( MedSir ) Como Sponsor ... Ha Iniciado Ya la Fase I/II Del Ensayo LUPER Para Small-Cell Lung Cancer .

Merck Intento Conseguir que Keytruda Pudiera Ser un Tratamiento de Primera Línea para Small-Cell Lung Cancer ... ¡ Y Fracaso en el Intento !! . 

MERCK con Keytruda el Año Pasado Consiguió Por Fin un Ok para el Tratamiento de Small-Cell Lung Cancer ... Pero  Solo Para Tercera Línea . 

Por lo Tanto MERCK Continuará en el Intento de Poder Conseguir Algún Día Que Keytruda Pueda Ser un Tratamiento de Primera Línea de Small Cell Lung Cancer ... 

***************************************

ZepZelCaTM  ( Lurbinectedin ) Combined With Keytruda ( Pembrolizumab ) in Small Cell Lung Cancer. (LUPER) .

Sponsor : Antonio Calles Blanco

Collaborators :

MedSIR

PharmaMar

Merck Sharp & Dohme Corp.

First Enrollment in The LUPER Study .

We are thrilled to communicate that the Luper study recruitment is underway!

Luper is a Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study to assess the efficacy of Lurbinectedin (PM01183) in Combination with Pembrolizumab in Patients with Relapsed Small Cell Lung Cancer .

We aim to demonstrate that the combination of PM01183 and pembrolizumab will result in clinical benefit and increase the survival of patients with relapsed SCLC, compared to the standard of care in this setting.

The Luper study includes pharmacokinetics, pharmacogenomics, pharmacogenetics and, several biomarkers analysis. Upon MTD and RD determination (current stage I) additional 30 patients will be included for efficacy assessment in stage II.